Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)

About this update from Quest Pharmatech Inc.

[{"type":"text","content":"\n\n\n\n\n\nTSX Venture: QPT\n\n\nEDMONTON, Nov. 1, 2011 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT)\n (\"Quest\" or the \"Company\"), a pharmaceutical company developing and\n commercializing products for the treatment of cancer, today announced\n that it will be making a presentation at the 2nd Biennial Meeting of the Asian Society of Gynecologic Oncology, in\n Seoul, South Korea, November 3-5. The presentation, entitled \"Targeting\n Dendritic Cells to Create a More Powerful Immune Response: A New\n Approach for the Immunotherapy of Ovarian Cancer using anti-CA125 MAb,\n Oregovomab\", will be presented by Dr. Chris Nicodemus, Chief Scientific\n Officer of Advanced Immune Therapeutics and Chairman of Quest's\n Clinical Advisory Board. Dr. Jonathan S. Berek, Professor and Director,\n Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford\n University School of Medicine, and Chair, Cooperative Ovarian Cancer\n Group, Stanford, California , is one of the co-authors of this\n presentation, along with Dr. Madi R. Madiyalakan, CEO of Quest. Dr.\n Berek has also been invited to make a presentation on 'Genetics of\n Ovarian Cancer' during the conference.\n\n\nThe Company's presentation will highlight its clinical experience with\n the immunotherapy of ovarian cancer using oregovomab, its unique\n mechanism in targeting dendritic cells to activate cytotoxic T cell\n responses, and the Company's strategy of using combinatorial therapies\n (chemotherapy and/or immuno-adjuvants) to better mobilize anti-tumor\n immunity. Dendritic cell based immunotherapeutic strategies are gaining\n momentum in recent days, especially after the award of this year's\n Noble Prize in Medicine for the discovery of the central role of\n dendritic cells in mobilizing the adaptive immune system.\n\n\n\"With a large shareholder base in South Korea, this is an excellent\n opportunity for Quest to present to the Asian gynecologic oncology\n community our unique approach for immunotherapy of ovarian cancer\",\n said Dr. Madiyalakan, who will also be attending the ASGO conference.\n\n\nThe Company is in the process of translating its valuable intellectual\n property into commercial success by conducting three carefully planned\n proof-of-concept clinical trials to establish the superiority of\n combinatorial immunotherapy either with front-line chemothera...

More updates from Quest Pharmatech Inc.